title: CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells.
abstract: Undifferentiated nasopharyngeal carcinoma (NPC) is latently infected with EBV and expresses a restricted number of viral proteins. Studies in healthy virus carriers have demonstrated that at least some of these proteins can act as targets for HLA class I-restricted CTLs. Therefore we have explored the possibility of a CTL-based therapy for NPC by characterizing EBV-specific CTL responses in 10 newly diagnosed NPC cases and 21 healthy virus carriers from Southeast Asia. Using the autologous EBV-transformed lymphoblastoid cell line, virus-specific CTL were reactivated in vitro from PBMC, cloned, and screened for cytotoxicity against target cells expressing individual EBV proteins from recombinant vaccinia vectors. EBV-specific CTLs were identified in 6 of 10 patients and 14 of 21 controls and mainly targeted the EBV nuclear Ag 3 (EBNA3) family of viral latent proteins. However, in 3 of 10 patients and 11 of 21 controls, CTLs specific for the NPC-associated protein LMP2 were also detected, albeit at low frequency. EBV-specific CTLs were detected in tumor biopsy material obtained from 3 of 6 of the patients, indicating that functional CTL are present at the tumor site, but none was specific for tumor-associated viral proteins. To assess the Ag-presenting function in NPC we studied two NPC-derived cell lines (C15 and c666.1) and demonstrated that both were capable of processing and presenting endogenously synthesized protein to HLA class I-restricted CTL clones. Overall, our data provide a sound theoretical basis for therapeutic strategies that aim to boost or elicit LMP2-specific CTL responses in NPC patients.
authors.affiliation: CRC Institute for Cancer Studies, University of Birmingham, Edgbaston, United Kingdom. s.p.lee@bham.ac.uk
authors.forename: S P
authors.initials: SP
authors.lastname: Lee
authors.forename: A T
authors.initials: AT
authors.lastname: Chan
authors.forename: S T
authors.initials: ST
authors.lastname: Cheung
authors.forename: W A
authors.initials: WA
authors.lastname: Thomas
authors.forename: D
authors.initials: D
authors.lastname: CroomCarter
authors.forename: C W
authors.initials: CW
authors.lastname: Dawson
authors.forename: C H
authors.initials: CH
authors.lastname: Tsai
authors.forename: S F
authors.initials: SF
authors.lastname: Leung
authors.forename: P J
authors.initials: PJ
authors.lastname: Johnson
authors.forename: D P
authors.initials: DP
authors.lastname: Huang
mesh_terms: D000328:Adult; D000368:Aged; D000595:Amino Acid Sequence; D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D002461:Cell Line, Transformed; D003602:Cytotoxicity, Immunologic; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D008213:Lymphocyte Activation; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D008969:Molecular Sequence Data; D009303:Nasopharyngeal Neoplasms / Q000097:blood / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000821:virology; D014407:Tumor Cells, Cultured; D014412:Tumor Virus Infections / Q000097:blood / Q000276:immunology* / Q000473:pathology
chemical_list: D018984:Epitopes, T-Lymphocyte